Cartesian’s Off-the-shelf RNA Therapy for Myeloma Enters Clinical Trials
Regenerative medicine for cancer is transitioning from patient-derived/ autologous immune cells to off-the-shelf immune-cell therapy to ensure standardised quality and quantity of engineered cells which can be expanded to treat multiple patients with repeat dosing.
GO Prime with only $1.49 now
LATEST
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115